Stimulant prescription for ADHD in people with a past history of anorexia nervosa.

IF 1.7 4区 医学 Q4 PSYCHIATRY
Australasian Psychiatry Pub Date : 2026-10-01 Epub Date: 2026-04-12 DOI:10.1177/10398562261441536
Romi Goldschlager, Karen Goldschlager, Lucia Porta Cubas, Jayashri Kulkarni
{"title":"Stimulant prescription for ADHD in people with a past history of anorexia nervosa.","authors":"Romi Goldschlager, Karen Goldschlager, Lucia Porta Cubas, Jayashri Kulkarni","doi":"10.1177/10398562261441536","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundADHD is a common neurodevelopmental disorder. Stimulants are the gold standard treatment resulting in measurable improvements in associated functional impairment. However, people with a history of comorbid anorexia nervosa (AN), an illness characterised by restricted intake and malnutrition, find it challenging to access stimulant treatment. In our clinical experience, amidst a scarce safety-profile for this population, stimulants are ceased or withheld due to concerns about appetite suppression, weight loss, and cardiac risks. We responded to the paucity of literature by reviewing the cases of people with ADHD and a history of AN who have received stimulant-treatment.MethodWe reviewed the medical records and personal experiences of six community patients with ADHD and a history of AN, to assess the safety and acceptability of stimulants.ResultsSide-effects included appetite suppression and stimulant induced weight loss. This did not appear to exacerbate AN-pathology. Patients experienced subjective improvement in ADHD pathology, attenuation of the negative impacts of ADHD on AN, and subjective improvements in anxiety, depression, and suicidality.ConclusionThese preliminary findings indicate safety and acceptability for the careful use of stimulants in people with ADHD and a history of AN and paves the way for larger studies to demonstrate clinical benefit.</p>","PeriodicalId":8630,"journal":{"name":"Australasian Psychiatry","volume":" ","pages":"464-472"},"PeriodicalIF":1.7000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10398562261441536","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/12 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundADHD is a common neurodevelopmental disorder. Stimulants are the gold standard treatment resulting in measurable improvements in associated functional impairment. However, people with a history of comorbid anorexia nervosa (AN), an illness characterised by restricted intake and malnutrition, find it challenging to access stimulant treatment. In our clinical experience, amidst a scarce safety-profile for this population, stimulants are ceased or withheld due to concerns about appetite suppression, weight loss, and cardiac risks. We responded to the paucity of literature by reviewing the cases of people with ADHD and a history of AN who have received stimulant-treatment.MethodWe reviewed the medical records and personal experiences of six community patients with ADHD and a history of AN, to assess the safety and acceptability of stimulants.ResultsSide-effects included appetite suppression and stimulant induced weight loss. This did not appear to exacerbate AN-pathology. Patients experienced subjective improvement in ADHD pathology, attenuation of the negative impacts of ADHD on AN, and subjective improvements in anxiety, depression, and suicidality.ConclusionThese preliminary findings indicate safety and acceptability for the careful use of stimulants in people with ADHD and a history of AN and paves the way for larger studies to demonstrate clinical benefit.

有神经性厌食症病史的人的ADHD兴奋剂处方。
背景:adhd是一种常见的神经发育障碍。兴奋剂是金标准治疗,可显著改善相关功能障碍。然而,有共病性神经性厌食症(AN)病史的人(AN是一种以限制摄入和营养不良为特征的疾病)发现很难获得兴奋剂治疗。在我们的临床经验中,在这一人群缺乏安全性的情况下,由于对食欲抑制、体重减轻和心脏风险的担忧,兴奋剂被停止或扣留。我们通过回顾患有多动症和AN病史的人接受兴奋剂治疗的病例来回应文献的缺乏。方法回顾性分析6例有AN病史的社区ADHD患者的医疗记录和个人经历,评价兴奋剂的安全性和可接受性。结果副反应包括食欲抑制和兴奋剂引起的体重下降。这似乎并没有加重an病理。患者经历了ADHD病理的主观改善,ADHD对AN的负面影响减弱,焦虑、抑郁和自杀倾向的主观改善。结论:这些初步研究结果表明,对于有AN病史的ADHD患者谨慎使用兴奋剂是安全和可接受的,并为更大规模的研究证明其临床益处铺平了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Australasian Psychiatry
Australasian Psychiatry 医学-精神病学
CiteScore
2.80
自引率
5.60%
发文量
159
审稿时长
6-12 weeks
期刊介绍: Australasian Psychiatry is the bi-monthly journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP) that aims to promote the art of psychiatry and its maintenance of excellence in practice. The journal is peer-reviewed and accepts submissions, presented as original research; reviews; descriptions of innovative services; comments on policy, history, politics, economics, training, ethics and the Arts as they relate to mental health and mental health services; statements of opinion and letters. Book reviews are commissioned by the editor. A section of the journal provides information on RANZCP business and related matters.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书